Deutsch  |  English   

GenoType PAI-1

Your test system for the definitive detection of two polymorphisms in the PAI-1 gene

Every year in Germany, several thousand people die from the consequences of vessel occlusions, such as a heart attack or pulmonary embolism.
Risk factors for such a vessel occlusion include, for example, increased blood lipid values, and also the body’s own substances can promote the development of occlusions. Thus an increase in the plasminogen activator inhibitor type 1 (PAI-1) level is also a risk factor for venous and arterial thrombosis PAI-1 is responsible for inhibiting two proteins which play an important role in the re-dissolution of a thrombus. An increased PAI-1 level thus leads to a greater inhibition of the proteins and therefore to a slower breakdown of the blood clot.
Two polymorphisms in the PAI-1 gene are associated with an increased PAI-1 level. Through insertion or deletion, either 4 or 5 guanine nucleotides may be present at position –675. If the 4G allele is present, there is an increased risk for venous thrombosis, primarily if additional thrombosis-related mutations are also present. In addition, for this genotype, an increased risk of myocardial infarcts and early miscarriages has also been established. Furthermore, the A-844G polymorphism in the PAI-1 gene is relevant. If the AA genotype is present, the risk of venous thrombosis is increased for Factor V Leiden carriers.
Since there is an increased risk of thrombosis in connection with thrombosis-related mutations, testing of the PAI-1 polymorphisms should be performed to assess individual thrombosis risk. In addition, it is useful to test patients with coronary artery disease and high-risk pregnancies.

Our GenoType PAI-1 test system allows you to detect with certainty the two polymorphisms and thus assess individual thrombosis risk.

reaction zones GenoType PAI-1

Your benefits with GenoType PAI-1

  • No limitation: the PAI-1 level in the blood is affected by various factors, such as, for example, glucose or also insulin. Therefore, biochemical methods only allow documentation of the actual situation. An increased PAI-1 level over the long term, by contrast, is only conditionally detected. Testing the genetic foundation is therefore of use and is recommended.
  • Definite result: if the test is not processed under optimal conditions, this will be indicated by an internal control.
  • Simple evaluation: using an evaluation template, the test result can be read rapidly and clearly.


Not all of our products are available in every country. Please contact your local sales representative for availability of this IVD product in your country.

At a glance
Molecular genetic assay for analysis of the -675 4G/5G and A-844G polymorphisms of the PAI-1 gene

Starting material:
EDTA/Citrate blood

DNA Isolation:

Order number: 

  • 12 tests  No. 222
DNASTRIP technology

Instruction for Use (IFU)
Evaluation sheet
Overview equipment programs

Information request: